Enanta Pharmaceuticals Inc (NASDAQ: ENTA) on Monday, soared 9.87% from the previous trading day, before settling in for the closing price of $10.33. Within the past 52 weeks, ENTA’s price has moved between $4.09 and $15.34.
The company achieved an average annual earnings per share of 31.62%. With a float of $26.05 million, this company’s outstanding shares have now reached $27.88 million.
Enanta Pharmaceuticals Inc (ENTA) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Enanta Pharmaceuticals Inc is 6.56%, while institutional ownership is 66.22%. The most recent insider transaction that took place on Feb 12 ’25, was worth 256,050. In this transaction President and CEO of this company bought 45,000 shares at a rate of $5.69, taking the stock ownership to the 846,638 shares. Before that another transaction happened on Dec 06 ’24, when Company’s Chief Product Strategy Officer sold 2,283 for $8.06, making the entire transaction worth $18,401. This insider now owns 29,305 shares in total.
Enanta Pharmaceuticals Inc (ENTA) Recent Fiscal highlights
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -1.36 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.92) by -0.44. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.02 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 31.62% per share during the next fiscal year.
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) Trading Performance Indicators
Enanta Pharmaceuticals Inc (ENTA) is currently performing well based on its current performance indicators. A quick ratio of 5.00 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.05.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.32, a number that is poised to hit -1.03 in the next quarter and is forecasted to reach -3.27 in one year’s time.
Technical Analysis of Enanta Pharmaceuticals Inc (ENTA)
Compared to the last year’s volume of 0.4 million, its volume of 1.64 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 43.67%.
During the past 100 days, Enanta Pharmaceuticals Inc’s (ENTA) raw stochastic average was set at 61.30%, which indicates a significant increase from 51.87% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.48 in the past 14 days, which was higher than the 0.61 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.42, while its 200-day Moving Average is $6.79. Nevertheless, the first resistance level for the watch stands at $11.88 in the near term. At $12.42, the stock is likely to face the second major resistance level. The third major resistance level sits at $13.24. If the price goes on to break the first support level at $10.52, it is likely to go to the next support level at $9.70. Now, if the price goes above the second support level, the third support stands at $9.16.
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) Key Stats
Market capitalization of the company is 327.48 million based on 21,378K outstanding shares. Right now, sales total 67,640 K and income totals -116,050 K. The company made 18,310 K in profit during its latest quarter, and -18,260 K in sales during its previous quarter.
